AGP Executive Report
Last update: 10 hours agoNew Treatment: The European Commission has approved Zealand Pharma’s Zeydovio for adults with short bowel syndrome, the first major European treatment advance for the condition in more than a decade. RSV Protection: EU medicines advisers support extending Merck’s ENFLONSIA protection to high-risk children through a second RSV season. The European Commission is expected to decide within two months; the proposed coverage includes Liechtenstein. Kidney Cancer: Advisers also recommend belzutifan plus lenvatinib for advanced clear-cell kidney cancer after immunotherapy. The combination improved progression-free survival in a trial, though overall survival did not reach statistical significance; a final decision is expected within two months and would cover Liechtenstein. Emerging Infection: France has reported the first known human Shamonda virus infection. The patient, an older man with serious underlying illness, died; investigators are assessing the virus’s role. Health officials say one case does not establish a wider public threat.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
